Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466669 | 0.82 | MEN1 (0.65) | MEN1KMT2AUSP2FAAHGRIN2B | |
| SCHEMBL12685786 | 0.82 | MEN1 (0.65) | MEN1KMT2AUSP2FAAHGRIN2B | |
| SCHEMBL4956677 | 0.80 | GRIN1 (0.68) | FAAHGRIN2BGRIN1 | |
| SCHEMBL12685780 | 0.79 | MEN1 (0.85) | MEN1KMT2AFAAHGRIN2B | |
| SCHEMBL12685841 | 0.78 | MEN1 (0.70) | MEN1KMT2AFAAHGRIN2B | |
| SCHEMBL12685846 | 0.77 | MEN1 (0.85) | MEN1KMT2AFAAHGRIN2B | |
| SCHEMBL12466443 | 0.76 | MEN1 (0.58) | MEN1KMT2AUSP2FAAHGRIN2B | |
| Trifluoroacetic Acid SCHEMBL4578256 | 0.76 | GRIN1 (0.62) | GRIN2BGRIN1 | |
| Hydrochloric Acid SCHEMBL12466326 | 0.76 | MEN1 (0.83) | MEN1KMT2AFAAHGRIN2B | |
| SCHEMBL12466338 | 0.76 | MEN1 (0.64) | MEN1KMT2AUSP2MAPK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | claimed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | claimed |
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | disclosed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | F2RL1, F2R, F2RL3 | MEN1 1376/4885KMT2A 2337/4885USP2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.